ASCLETIS-B (01672) announced its interim results for the six months ended June 30, 2025. The group achieved total revenue of RMB 104 million, representing a 111.4% year-on-year increase. Research and development costs reached RMB 147 million, up 10.9% compared to the same period last year. Loss attributable to equity shareholders was RMB 87.951 million, representing a 32.5% reduction year-on-year, with loss per share of 9.14 cents.

During the reporting period and up to the date of this announcement, the group achieved significant progress across its metabolic disease pipeline, immune disease pipeline, and expanded indication product pipeline:

ASC30 once-daily oral tablet for obesity treatment: In the U.S. Phase Ib study, after 28 days of treatment, placebo-adjusted mean weight loss from baseline reached up to 6.5%, demonstrating its potential as a best-in-class candidate for obesity treatment. The group initiated a U.S. Phase IIa study and rapidly completed enrollment of 125 subjects within just over one month.

ASC30 monthly or less frequent subcutaneous injection for obesity treatment: In the U.S. Phase Ib study, a single subcutaneous injection demonstrated a 36-day half-life in obesity patients, supporting monthly or less frequent dosing. The group initiated a U.S. Phase IIa clinical study and completed dosing of the first cohort of subjects.

ASC47 monthly or less frequent subcutaneous injection for muscle-sparing obesity treatment: Demonstrated a 40-day half-life in obesity patients. The group initiated a U.S. study of ASC47 in combination with semaglutide and completed enrollment of all 28 obese subjects.

ASC50 oral small molecule interleukin-17 (IL-17) inhibitor: Initiated a U.S. Phase I clinical study and completed dosing of the first cohort of healthy subjects.

Once-daily oral fatty acid synthase (FASN) inhibitor denifanstat (ASC40) for acne treatment: In the Phase III study, all primary, key secondary, and secondary endpoints achieved highly statistically significant and clinically meaningful improvements compared to placebo, demonstrating favorable safety and tolerability profiles. Denifanstat (ASC40) showed superior efficacy and favorable safety characteristics in the Phase III trial, potentially achieving a major breakthrough in acne treatment.

These achievements highlight the group's robust R&D capabilities, excellent execution, and long-term commitment to developing globally best-in-class/first-in-class pipeline drugs to address unmet clinical needs.